Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 37Blood Pressure and Hypertension StudiesMedication Adherence and ComplianceCardiovascular Health and Disease Prevention

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Compliance and Antihypertensive Efficacy of Amlodipine Compared With Nifedipine Slow-Release

Mounier-Vehier, C·1998·American Journal of Hypertension

Abstract

Poor compliance is a principal cause of treatment failure in hypertensive patients. Once-daily dosing improves compliance, but 24-h antihypertensive activity should be provided. The compliance, efficacy, and safety of amlodipine and nifedipine slow-release (SR) were compared in patients with mild-to-moderate essential hypertension recruited among 24 centers in France. After a 2-week washout period, 103 patients were randomized to 12 weeks of 5 to 10 amlodipine mg once daily (n = 55) or 20 mg nifedipine SR twice daily (n = 48). Compliance was calculated by electronic drug monitoring. Efficacy was measured by ambulatory and casual BP recordings. Patients receiving amlodipine demonstrated better compliance than patients receiving nifedipine SR with respect to compliance index (the total number of doses taken divided by the total number of doses prescribed, expressed as a percentage; 98.3% v 87%; P < .0001), days on which the correct number of doses were taken (92.5% v 74.8%; P < .0001), and prescribed doses taken on schedule (88.7% v 71.6%; P < .0001). Absolute and relative therapeutic coverage were higher in patients receiving amlodipine than nifedipine SR (P < .0001). Mean SBP and DBP decreased equally in both groups, although amlodipine offered better BP control compared with nifedipine SR at specific times of day. Fewer patients had high nocturnal SBP with amlodipine (39.3%) than nifedipine SR (71.4%; P = .042). Adverse events and treatment withdrawals occurred less frequently in amlodipine-treated patients than in nifedipine SR-treated patients. Amlodipine (5 to 10 mg) once daily provides improved compliance, better 24-h BP control, and fewer adverse events than 20 mg nifedipine SR twice daily in patients with mild-to-moderate hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0895-7061(97)00485-8

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 37

Metadata

Authors
Mounier-Vehier, C.
Venue
American Journal of Hypertension
Published
1998-04
Volume
11
Issue
4
Pages
478-486
ISSN
0895-7061 (ISSN-L)
OpenAlex
W1964491414
Cited by
37
References
24
Citations by year
2026: 3 · 2023: 1 · 2021: 1 · 2019: 1 · 2014: 1 · 2013: 3 · 2012: 2
FWCI
1.26
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
amlodipine, essential hypertension, medication adherence, antihypertensive efficacy, once-daily dosing, 24-hour blood pressure control, nocturnal blood pressure, calcium channel blockers, adverse events
MeSH terms
Adolescent, Adult, Aged, Antihypertensive Agents, Blood Pressure, Calcium Channel Blockers, Delayed-Action Preparations, Female, Humans, Hypertension, Male, Middle Aged, Nifedipine, Patient Compliance, Treatment Outcome, Amlodipine, Blood Pressure Monitoring, Ambulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Compliance and Antihypertensive Efficacy of Amlodipine Compared With Nifedipine Slow-Release. https://app.cochat.ai/papers/10.1016/s0895-7061(97)00485-8
The paper
Mounier-Vehier, C. (1998). Compliance and Antihypertensive Efficacy of Amlodipine Compared With Nifedipine Slow-Release. American Journal of Hypertension. https://doi.org/10.1016/s0895-7061(97)00485-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.